We defined AUD patients as having progressive liver disease if they had CAP values ≥250 dB/m and AST >40 IU/L, ALT >40 IU/L (steato-hepatitis) and/or fibrosis stage 2 or higher (steato-fibrosis) by Fibroscan (cut-off 7.9 kPa). This evidence concerns the gene GPT and Hepatitis.